Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Perspective Therapeutics Inc (CATX)

Perspective Therapeutics Inc (CATX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 153,880
  • Shares Outstanding, K 74,338
  • Annual Sales, $ 1,450 K
  • Annual Income, $ -79,280 K
  • EBIT $ -85 M
  • EBITDA $ -60 M
  • 60-Month Beta 1.02
  • Price/Sales 108.39
  • Price/Cash Flow N/A
  • Price/Book 0.65

Options Overview Details

View History
  • Implied Volatility 151.85% ( +26.42%)
  • Historical Volatility 134.11%
  • IV Percentile 16%
  • IV Rank 9.86%
  • IV High 1,031.38% on 09/30/25
  • IV Low 55.61% on 04/17/25
  • Put/Call Vol Ratio 0.00
  • Today's Volume 410
  • Volume Avg (30-Day) 477
  • Put/Call OI Ratio 0.72
  • Today's Open Interest 11,834
  • Open Int (30-Day) 7,893

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.37
  • Number of Estimates 7
  • High Estimate -0.31
  • Low Estimate -0.43
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.00 +4.00%
on 11/13/25
5.14 -59.53%
on 10/16/25
-2.76 (-57.02%)
since 10/14/25
3-Month
2.00 +4.00%
on 11/13/25
5.39 -61.40%
on 10/13/25
-1.82 (-46.67%)
since 08/14/25
52-Week
1.60 +30.00%
on 04/09/25
8.93 -76.71%
on 11/15/24
-6.84 (-76.68%)
since 11/14/24

Most Recent Stories

More News
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Updated interim results from the Company’s [ 212 Pb]VMT-α-NET Phase 1/2a study supporting the therapy’s compelling overall clinical profile at the 5 mCi dose were presented at the ESMO Congress...

CATX : 2.08 (+0.48%)
Perspective Therapeutics to Participate in Upcoming November Conferences

SEATTLE, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc.  ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments...

CATX : 2.08 (+0.48%)
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

SEATTLE, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc.  ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments...

CATX : 2.08 (+0.48%)
Bank of America Securities Sticks to Their Hold Rating for Perspective Therapeutics (CATX)

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Hold rating on Perspective Therapeutics, with a price target of $5.00. The company’s shares closed yesterday at...

CATX : 2.08 (+0.48%)
Oppenheimer Keeps Their Buy Rating on Perspective Therapeutics (CATX)

Oppenheimer analyst Jeff Jones maintained a Buy rating on Perspective Therapeutics today and set a price target of $14.00. The company’s shares closed yesterday at $3.47.Elevate Your Investing Strategy:...

CATX : 2.08 (+0.48%)
Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors

SEATTLE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc.  ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments...

CATX : 2.08 (+0.48%)
Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

First patient dosed with [ 212 Pb]VMT01 3.0 mCi in combination with nivolumab [ 212 Pb]VMT01 3.0 mCi single agent dose Cohort re-opened SEATTLE, Sept. 15, 2025 (GLOBE NEWSWIRE) --  ...

CATX : 2.08 (+0.48%)
Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer

SEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers...

CATX : 2.08 (+0.48%)
Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers...

CATX : 2.08 (+0.48%)
Perspective Therapeutics to Participate in Upcoming September Conferences

SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers...

CATX : 2.08 (+0.48%)

Business Summary

Perspective Therapeutics Inc. is a medical technology and radiopharmaceutical company which provide advanced treatment applications for cancers. The Company is the sole producer of Cesium-131 brachytherapy seeds. Perspective Therapeutics Inc., formerly known as Isoray Inc., is based in RICHLAND, Wash....

See More

Key Turning Points

3rd Resistance Point 2.38
2nd Resistance Point 2.31
1st Resistance Point 2.19
Last Price 2.08
1st Support Level 2.00
2nd Support Level 1.93
3rd Support Level 1.81

See More

52-Week High 8.93
Fibonacci 61.8% 6.13
Fibonacci 50% 5.27
Fibonacci 38.2% 4.40
Last Price 2.08
52-Week Low 1.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar